サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1737525

オミックス研究における人工知能の世界市場

Artificial Intelligence in Omics Studies

出版日
ページ情報
英文 204 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
オミックス研究における人工知能の世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 204 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

オミックス研究における人工知能の世界市場は2030年までに45億米ドルに達する見込み

2024年に9億1,350万米ドルと推定されるオミックス研究における人工知能の世界市場は、2024年から2030年にかけてCAGR 30.4%で成長し、2030年には45億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるAIソフトウェアは、CAGR27.7%を記録し、分析期間終了時には27億米ドルに達すると予測されます。AIサービス分野の成長率は、分析期間でCAGR 35.3％と推定されます。

米国市場は2億4,010万米ドルと推定、中国はCAGR 28.9％で成長予測

米国のオミックス研究における人工知能市場は、2024年に2億4,010万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを28.9%として、2030年までに6億7,970万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ27.3％と26.5％と予測されています。欧州では、ドイツがCAGR 21.3%で成長すると予測されています。

世界のオミックス研究における人工知能市場- 主要動向と促進要因まとめ

オミックス研究の進化に人工知能が不可欠になった理由とは？

人工知能（AI）は、ゲノミクス、トランスクリプトミクス、プロテオミクス、メタボロミクス、エピゲノミクスを含むオミクス研究において、従来のバイオインフォマティクスでは複雑かつ膨大すぎる膨大な高次元生物学的データセットの解析を可能にすることで、変革をもたらす存在になりつつあります。オミックス技術は大量の多層データを生成するため、意味のある生物学的パターンや疾患メカニズム、治療標的を明らかにするためには、統合的かつ動的なモデリングアプローチが必要となることが多いです。AI、特に機械学習（ML）とディープラーニング・アルゴリズムは、相関関係の特定、遺伝子と疾患の関連性の予測、タンパク質構造のモデル化、バイオマーカーの発見において、従来の手法よりもはるかに高い精度と拡張性を持つことが証明されつつあります。

ライフサイエンスが個別化されたシステムレベルの医療へとシフトするにつれ、クロスオミクスデータを実用的な洞察へと合成できる計算ツールの必要性がますます高まっています。AI駆動型プラットフォームは、隠れたパターンを検出し、次元を減らし、早期診断、薬剤反応プロファイリング、疾患進行モニタリングの中心となる予測モデルを生成することで、これを促進します。オミックス研究とAIの融合は、生物医学研究者、製薬会社、プレシジョン・メディシン・プラットフォームが仮説を立て、発見を加速し、個別化治療戦略に近づく方法を再定義しつつあります。

AIモデルはどのようにマルチオミックス統合と予測精度を高めているのか？

オミックス研究における人工知能の応用は、ゲノム、トランスクリプトーム、プロテオーム、メタボロームの各レイヤーにまたがるデータを統合し、全体的な生物学的モデルを構築するマルチオミックス統合において、特に大きな変革をもたらしています。サポートベクターマシン（SVM）、ランダムフォレスト、ディープニューラルネットワークなどの機械学習アルゴリズムにより、研究者は分子シグネチャーと、がんサブタイプ、神経変性疾患、希少疾患などの複雑な表現型との潜在的関連性を明らかにすることができます。AIモデルは、マルチオミクス解析における共通の課題である、データの不均一性、欠損値、非線形関係の管理に優れています。

畳み込みニューラルネットワーク（CNN）やオートエンコーダなどのディープラーニングアーキテクチャは、遺伝子型から表現型へのリンクのマッピング、タンパク質のフォールディング予測（構造生物学におけるAlphaFoldのブレークスルーなど）、新規創薬ターゲットの同定などに利用されています。自然言語処理（NLP）ツールは、構造化されていない生物学文献から知識を抽出し、オミクスのアノテーションや仮説を充実させています。さらに、教師なし学習は、事前にラベリングすることなく、患者層別化や疾患分類のためにオミックスデータをクラスタリングするのに役立っています。このようなAIの能力により、研究者は記述的分析から予測的分析、さらには処方的分析へと移行し、新たなデータの入力に応じて進化することができる、動的な学習ベースの生物学モデルを作成することができるようになります。

オミックス研究における人工知能はどこで勢いを増し、どの分野が応用をリードしているのか？

オミックス研究における人工知能アプリケーションは、学術研究、製薬研究開発、精密腫瘍学、希少疾患診断、農業バイオテクノロジーで勢いを増しています。北米が市場を独占しており、主要機関、ゲノミクス新興企業、バイオ製薬企業がバイオマーカー探索の加速、試験デザインの最適化、コンパニオン診断薬の開発にAIを導入しています。欧州、特にドイツ、英国、北欧諸国では、EUが資金提供する研究枠組みを通じて、AIを活用したオミックス共同研究が急成長しています。一方、中国、日本、韓国を中心とするアジア太平洋地域では、国家的精密医療構想や集団シーケンシングプロジェクトを支援するため、AIゲノミクス・プラットフォームへの戦略的投資が行われています。

がん研究は依然として最も活発な分野で、AIモデルは分子サブタイプに基づいて腫瘍を層別化し、治療反応を予測し、リアルタイムのオミックスデータを使用して耐性メカニズムを監視するために適用されています。ファーマコゲノミクスでは、AIが遺伝子型と薬物反応プロファイルを結びつけることによって、薬物代謝研究を指導しています。アルツハイマー病やパーキンソン病などの神経変性疾患も注目を集めており、AIモデルがマルチオミクスや画像データを解析して、初期のバイオマーカーや進行パターンを明らかにしています。農業分野では、AIを活用したオミックスによって、気候変動に強い作物の開発、形質選択、病原菌耐性の最適化が可能になりつつあります。このような幅広い応用範囲は、学際的な共同研究を促進し、新たな商業化の道筋を生み出しています。

オミックス研究における人工知能の世界的成長の原動力は？

オミックス研究における人工知能の成長は、ハイスループットシーケンス技術の爆発的な普及、マルチオミクスプラットフォームの手頃な価格、個別化医療における統合的解析の重要なニーズなど、いくつかの要因によってもたらされています。主要な推進力は、大規模コホート研究、臨床試験、および集団全体のゲノム構想によるオミックスデータ生成の急激な増加です。AIは、これらのデータセットから価値を引き出し、診断、治療、予防ヘルスケアのための実用的な洞察に変えるために必要な計算インフラを提供します。

政府、医療システム、民間利害関係者による支援政策や投資も、市場拡大に拍車をかけています。NIHのAll of Us Research Program、UK Biobank、China Precision Medicine initiativeなどのイニシアチブでは、ゲノム解釈やリスクモデリングのためにAIを導入しています。クラウドベースのバイオインフォマティクスプラットフォームやAI-as-a-サービス・モデルは、研究機関や中規模のバイオテクノロジー企業による導入の障壁をさらに低くしています。データ共有フレームワークの強化は、データの匿名化や連携学習の進歩と相まって、モデルの堅牢性を最大限に高めつつ、プライバシーの懸念に対処するのに役立っています。AIが生物医学研究を再構築し続ける中、重大な疑問が浮上しています。人工知能は、スケーラブルで倫理的、かつ臨床的に実行可能なオミクスの主流ヘルスケアおよび集団レベルの疾病予防への統合を可能にすることができるのだろうか？

セグメント

提供（ソフトウェア、サービス）、テクノロジー（シーケンス、エピゲノミクス、プロテオミクス、メタボロミクス、その他のテクノロジー）、アプリケーション（腫瘍学、感染症、神経学、心血管疾患、免疫学、その他のアプリケーション）、エンドユーザー（学術・研究機関、バイオ製薬会社、その他のエンドユーザー）

調査対象企業の例（注目32社）

  • Agilent Technologies
  • Amazon Web Services
  • Anima Biotech
  • Antiverse
  • Atomwise
  • BenevolentAI
  • BGI Genomics
  • Bio-Rad Laboratories
  • Bruker Corporation
  • Caris Life Sciences
  • Danaher Corporation
  • Deep Genomics
  • Exscientia
  • Fabric Genomics
  • GE Healthcare
  • GeneDx
  • Genetic Leap
  • Healx
  • Illumina Inc.
  • Insilico Medicine

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP33463

Global Artificial Intelligence in Omics Studies Market to Reach US$4.5 Billion by 2030

The global market for Artificial Intelligence in Omics Studies estimated at US$913.5 Million in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 30.4% over the analysis period 2024-2030. AI Software, one of the segments analyzed in the report, is expected to record a 27.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the AI Services segment is estimated at 35.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$240.1 Million While China is Forecast to Grow at 28.9% CAGR

The Artificial Intelligence in Omics Studies market in the U.S. is estimated at US$240.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$679.7 Million by the year 2030 trailing a CAGR of 28.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 27.3% and 26.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 21.3% CAGR.

Global Artificial Intelligence in Omics Studies Market - Key Trends & Drivers Summarized

Why Is Artificial Intelligence Becoming Indispensable in the Evolution of Omics Research?

Artificial Intelligence (AI) is becoming a transformative force in omics studies-including genomics, transcriptomics, proteomics, metabolomics, and epigenomics-by enabling the analysis of vast, high-dimensional biological datasets that would otherwise be too complex and voluminous for traditional bioinformatics. Omics technologies generate massive quantities of multi-layered data, often requiring integrative and dynamic modeling approaches to uncover meaningful biological patterns, disease mechanisms, and therapeutic targets. AI, particularly machine learning (ML) and deep learning algorithms, is proving instrumental in identifying correlations, predicting gene-disease associations, modeling protein structures, and discovering biomarkers with far greater precision and scalability than conventional methods.

As life sciences shift toward personalized, systems-level medicine, the need for computational tools that can synthesize cross-omics data into actionable insights is becoming increasingly urgent. AI-driven platforms facilitate this by detecting hidden patterns, reducing dimensionality, and generating predictive models that are central to early diagnosis, drug response profiling, and disease progression monitoring. The convergence of omics research and AI is redefining how biomedical researchers, pharmaceutical companies, and precision medicine platforms develop hypotheses, accelerate discovery, and move closer to individualized treatment strategies.

How Are AI Models Enhancing Multi-Omics Integration and Predictive Accuracy?

The application of AI in omics is particularly transformative in multi-omics integration-combining data across genomic, transcriptomic, proteomic, and metabolomic layers to build holistic biological models. Machine learning algorithms, including support vector machines (SVMs), random forests, and deep neural networks, are enabling researchers to uncover latent associations between molecular signatures and complex phenotypes, such as cancer subtypes, neurodegenerative conditions, or rare diseases. AI models excel at managing data heterogeneity, missing values, and non-linear relationships-common challenges in multi-omics analytics.

Deep learning architectures, including convolutional neural networks (CNNs) and autoencoders, are being used to map genotype-to-phenotype links, predict protein folding (e.g., AlphaFold’s breakthrough in structural biology), and identify novel drug targets. Natural language processing (NLP) tools are extracting knowledge from unstructured biological literature to enrich omics annotations and hypotheses. Moreover, unsupervised learning is helping in clustering omics data for patient stratification and disease classification without prior labeling. These AI capabilities are empowering researchers to move from descriptive to predictive and even prescriptive analytics-creating dynamic, learning-based models of biology that can evolve with new data inputs.

Where Is AI in Omics Gaining Momentum and Which Fields Are Leading Applications?

AI applications in omics are gaining momentum in academic research, pharmaceutical R&D, precision oncology, rare disease diagnostics, and agricultural biotechnology. North America dominates the market, with leading institutions, genomics startups, and biopharma companies deploying AI to accelerate biomarker discovery, optimize trial designs, and develop companion diagnostics. Europe, particularly Germany, the U.K., and the Nordic countries, is seeing robust growth in AI-driven omics collaborations through EU-funded research frameworks. Meanwhile, Asia-Pacific-driven by China, Japan, and South Korea-is making strategic investments in AI genomics platforms to support national precision medicine initiatives and population-scale sequencing projects.

Cancer research remains the most active area, with AI models being applied to stratify tumors based on molecular subtypes, predict therapy response, and monitor resistance mechanisms using real-time omics data. In pharmacogenomics, AI is guiding drug metabolism studies by linking genotypes with drug response profiles. Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are also gaining attention, where AI models analyze multi-omics and imaging data to uncover early biomarkers and progression patterns. In the agricultural space, AI-powered omics is enabling the development of climate-resilient crops, trait selection, and pathogen resistance optimization. This broad scope of application is catalyzing interdisciplinary collaborations and creating new commercialization pathways.

What Is Driving the Global Growth of Artificial Intelligence in Omics Studies?

The growth in artificial intelligence in omics studies is driven by several factors, including the explosion of high-throughput sequencing technologies, the affordability of multi-omics platforms, and the critical need for integrative analytics in personalized medicine. A key driver is the exponential increase in omics data generation from large-scale cohort studies, clinical trials, and population-wide genome initiatives. AI provides the computational infrastructure necessary to extract value from these datasets-turning them into actionable insights for diagnostics, therapeutics, and preventive healthcare.

Supportive policies and investments from governments, health systems, and private stakeholders are also fueling market expansion. Initiatives like the NIH’s All of Us Research Program, UK Biobank, and the China Precision Medicine initiative are deploying AI for genomic interpretation and risk modeling. Cloud-based bioinformatics platforms and AI-as-a-service models are further lowering barriers for adoption by research institutions and mid-sized biotech firms. Enhanced data sharing frameworks, coupled with advances in data anonymization and federated learning, are helping address privacy concerns while maximizing model robustness. As AI continues to reshape biomedical research, a critical question emerges: Can artificial intelligence enable a scalable, ethical, and clinically actionable integration of omics into mainstream healthcare and population-level disease prevention?

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Omics Studies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Software, Services); Technology (Sequencing, Epigenomics, Proteomics, Metabolomics, Other Technologies); Application (Oncology, Infectious Diseases, Neurology, Cardiovascular Diseases, Immunology, Other Applications); End-User (Academic & Research Institutes, Biopharmaceutical Company, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Agilent Technologies
  • Amazon Web Services
  • Anima Biotech
  • Antiverse
  • Atomwise
  • BenevolentAI
  • BGI Genomics
  • Bio-Rad Laboratories
  • Bruker Corporation
  • Caris Life Sciences
  • Danaher Corporation
  • Deep Genomics
  • Exscientia
  • Fabric Genomics
  • GE Healthcare
  • GeneDx
  • Genetic Leap
  • Healx
  • Illumina Inc.
  • Insilico Medicine

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Artificial Intelligence in Omics Studies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AI Algorithms Unlock New Biological Insights Across Genomics, Transcriptomics, and Proteomics
    • Machine Learning Accelerates Target Discovery in Complex Multi-Omics Datasets
    • AI-Powered Pattern Recognition Enables Early Disease Biomarker Identification in Omics Studies
    • Integration of AI with Next-Generation Sequencing Platforms Enhances Data Interpretation Speed
    • Personalized Medicine Strategies Leverage AI to Decode Omics Complexity in Clinical Contexts
    • Multi-Omics Data Fusion Using AI Enhances Predictive Modeling of Disease Progression
    • AI Platforms Support Scalable Annotation and Classification of Large Omics Repositories
    • Deep Learning Models Identify Non-Obvious Biological Relationships Within Omics Networks
    • Regulatory Interest in Explainable AI Tools Strengthens Clinical Use of Omics-Based Diagnostics
    • AI Automation in Omics Pipelines Reduces Time-to-Insight for Drug and Biomarker Discovery
    • Pharma and Biotech R&D Pipelines Embrace AI in Omics to Cut Costs and Improve Yield
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence in Omics Studies Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence in Omics Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Biopharmaceutical Company by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Biopharmaceutical Company by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Epigenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Epigenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Proteomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Proteomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 36: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 60: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 64: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: China 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 66: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 78: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 82: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: France 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 84: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 102: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 106: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 108: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030

IV. COMPETITION